Article Details

Capitalizing on a gene therapy boom, Avrobio locks in $60M

Retrieved on: 2018-02-05 06:17:28

Tags for this article:

Click the tags to see associated articles and topics

Capitalizing on a gene therapy boom, Avrobio locks in $60M. View article details on hiswai:

Excerpt

<div>Early backers <b>Atlas Venture</b>, SV Health Investors, and Clarus Ventures also chipped in. It follows a successful Phase 1 trial for Avrobio's lead program in Fabry disease in 2017. While it was an N of 1 trial (involving just one person), the therapy delivered a complete response, restoring normal enzyme ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up